1---
2name: managing-pediatric-growth-disorders
3language: en
4description: Evaluates short stature and growth velocity with bone age interpretation and endocrine workup. Use when evaluating growth disorders, interpreting growth curves, or ordering growth workup.
5tags:
6 - management
7 - pediatrics
8metadata:
9 source: https://skillmd.com/skills/casemark/managing-pediatric-growth-disorders
10 author: casemark
11 practice_areas:
12 - Pediatrics
13 - Neonatology
14 - Adolescent Medicine
15 document_types:
16 - Management Report
17 skill_modes:
18 - Management
19 - Coordination
20---
21
22# Managing Pediatric Growth Disorders
23
24Evaluates short stature, tall stature, and abnormal growth velocity using WHO/CDC growth chart analysis, bone age radiography interpretation, mid-parental height targeting, endocrine workup algorithms, and criteria for growth hormone therapy referral. Differentiates normal variants (familial short stature, constitutional delay) from pathologic causes requiring intervention.
25
26## Why This Skill Exists
27
28Growth is the most sensitive indicator of a child's overall health. Deceleration in height velocity may be the first sign of celiac disease, hypothyroidism, growth hormone deficiency, Turner syndrome, or chronic systemic illness — often preceding other symptoms by months or years. Conversely, many children evaluated for short stature have normal variants (familial short stature or constitutional delay of growth and puberty) requiring only reassurance. This skill enforces systematic differentiation between normal and pathologic growth patterns and prevents both under-investigation of worrisome trajectories and unnecessary endocrine workup for normal variants.
29
30---
31
32## Checkpoint A — Intake Verification
33
34### Required Intake Questions
351. What is the child's age, sex, current height, and weight?
362. What are the serial height measurements over time (minimum 6-12 months of data)?
373. What is the birth length and birth weight? Was the child SGA?
384. What are the parents' heights (for mid-parental height calculation)?
395. What are the parents' pubertal timing histories (age of menarche for mother, growth spurt for father)?
406. Is there a family history of growth disorders, thyroid disease, or autoimmune conditions?
417. What is the child's Tanner stage (pubertal assessment)?
428. Does the child have chronic symptoms: fatigue, GI complaints, headaches, polyuria/polydipsia?
439. Is the child on any medications that might affect growth (corticosteroids, stimulants)?
4410. Has a bone age X-ray been obtained?
45
46### Required Documents
47- Serial height measurements plotted on WHO (< 2 years) or CDC (2-20 years) growth chart
48- Birth records (length, weight, gestational age)
49- Parental heights
50- Bone age radiograph result (if obtained)
51- Previous laboratory results (thyroid, IGF-1, celiac panel if done)
52- Pubertal staging documentation
53
54---
55
56## Step 1 — Growth Chart Analysis
57
58### When to Investigate
59- Height < 3rd percentile (or < -2 SD) for age and sex
60- Height significantly below mid-parental height target range
61- Height velocity < 25th percentile for age (see velocity thresholds below)
62- Crossing downward across 2 or more major percentile lines after age 2
63- Height discordant with weight (weight preserved but height decelerating suggests endocrine cause)
64
65### Expected Height Velocity by Age
66| Age | Normal Height Velocity (cm/year) |
67|-----|--------------------------------|
68| 0-1 year | 23-27 |
69| 1-2 years | 10-14 |
70| 2-3 years | 7.5-10 |
71| 3 years to puberty | 5-7 |
72| Puberty (girls) | 8-12 (peak at Tanner 2-3) |
73| Puberty (boys) | 10-14 (peak at Tanner 3-4) |
74
75> Height velocity < 4 cm/year in a prepubertal child aged 3+ years is abnormal and requires workup.
76
77### Mid-Parental Height (MPH) / Target Height
78- **Boys**: (mother's height cm + father's height cm + 13) / 2
79- **Girls**: (mother's height cm + father's height cm - 13) / 2
80- Target range: MPH ± 8.5 cm (represents ~2 SD)
81- If child's projected adult height (from bone age) falls outside target range, investigate
82
83---
84
85## Step 2 — Bone Age Interpretation
86
87### Obtaining Bone Age
88- Left hand and wrist AP radiograph (Greulich-Pyle atlas or Tanner-Whitehouse method)
89- Indications: short stature evaluation, pubertal assessment, growth prediction
90
91### Interpretation Patterns
92| Finding | Bone Age Relative to Chronological Age | Suggests |
93|---------|---------------------------------------|----------|
94| Normal variant short stature (FSS) | Bone age = chronological age | Familial short stature; adult height near MPH |
95| Constitutional delay (CDGP) | Bone age delayed (by 1-3 years) | Constitutional delay of growth and puberty; will be a "late bloomer"; adult height often normal |
96| Pathologic short stature | Bone age delayed + poor growth velocity | GH deficiency, hypothyroidism, chronic disease, Turner syndrome |
97| Bone age advanced | Bone age > chronological age | Precocious puberty, CAH, hyperthyroidism |
98
99### Predicted Adult Height
100- Use Bayley-Pinneau tables with bone age to predict adult height
101- Compare predicted adult height to mid-parental height target range
102- If predicted height falls within MPH range → reassuring for normal variant
103- If predicted height falls below MPH range → warrants further investigation
104
105---
106
107## Step 3 — Differentiating Normal Variants from Pathology
108
109### Familial Short Stature (FSS)
110- Parents short; child grows along a low percentile consistently
111- Bone age = chronological age
112- Puberty at normal time
113- Adult height: short, but within MPH range
114- **Management**: reassurance; no treatment indicated
115
116### Constitutional Delay of Growth and Puberty (CDGP)
117- Family history of late puberty (mother's menarche > 14, father's growth spurt > 15)
118- Child short for age but growing at normal velocity for bone age
119- Bone age delayed 1-3 years; puberty delayed
120- Adult height: usually normal (catches up during late adolescent growth spurt)
121- **Management**: reassurance; consider short course of low-dose sex steroids at age 13-14 (boys) if psychosocial distress is significant
122
123### Red Flags for Pathologic Short Stature
124- Height velocity < 4 cm/year (prepubertal)
125- Height < -3 SD for age
126- Disproportionate short stature (short limbs vs. trunk → skeletal dysplasia)
127- Dysmorphic features
128- Midline defects (cleft palate, single central incisor) → consider GH deficiency/pituitary abnormality
129- Declining height percentile (crossing down) after age 2
130- Weight gain with height deceleration (suggests hypothyroidism, Cushing syndrome)
131- Absent or delayed puberty beyond 13 (girls) or 14 (boys)
132
133---
134
135## Step 4 — Tiered Diagnostic Workup
136
137### Tier 1 — Initial Screen (For All Children With Concerning Growth)
138| Test | Purpose |
139|------|---------|
140| CBC | Chronic disease, anemia |
141| CMP | Renal disease, electrolyte abnormalities |
142| TSH and free T4 | Hypothyroidism |
143| Celiac panel (tTG-IgA + total IgA) | Celiac disease (may present with isolated short stature) |
144| ESR or CRP | Chronic inflammatory disease (IBD, JIA) |
145| IGF-1 and IGFBP-3 | GH axis screening (age- and Tanner-adjusted reference ranges) |
146| Bone age (left hand/wrist) | Skeletal maturity |
147
148### Tier 2 — Directed by Clinical Clues
149| Clue | Test |
150|------|------|
151| Female with unexplained short stature | Karyotype (Turner syndrome — 45,X — occurs in 1:2500 girls; may have no other features) |
152| Dysmorphic features | Chromosomal microarray or targeted genetic testing |
153| Disproportionate limbs | Skeletal survey, FGFR3 testing (achondroplasia) |
154| Midline defects, neonatal hypoglycemia | Pituitary MRI |
155| Low IGF-1 | GH stimulation testing (clonidine, arginine, or glucagon stim — performed by endocrinology) |
156| Obesity + short stature + striae | AM cortisol, 24-hour urine free cortisol (Cushing syndrome) |
157| Precocious puberty signs + advanced bone age | LH, FSH, estradiol/testosterone |
158| Chronic GI symptoms | Upper/lower endoscopy (celiac, IBD) |
159
160### Tier 3 — Subspecialty Referral
161- **Pediatric endocrinology**: GH stimulation testing, GH therapy initiation, precocious/delayed puberty management
162- **Genetics**: dysmorphic features, skeletal dysplasia, suspected syndromic diagnosis
163- **Pediatric GI**: suspected celiac disease not responding to diet, IBD, nutritional deficiency
164- **Pediatric nephrology**: chronic kidney disease affecting growth
165
166---
167
168## Step 5 — Growth Hormone Therapy Considerations
169
170### FDA-Approved Indications for GH Therapy in Children
171- Growth hormone deficiency (GHD) — confirmed by stimulation testing
172- Turner syndrome
173- Chronic renal insufficiency (pre-transplant)
174- Prader-Willi syndrome
175- SGA without catch-up growth by age 2-4
176- SHOX deficiency
177- Idiopathic short stature (ISS): height < -2.25 SD (controversial; less insurance coverage)
178- Noonan syndrome
179
180### GH Therapy Basics
181- Dose: 0.024-0.034 mg/kg/day SC injection (varies by indication; higher for Turner, ISS)
182- Monitoring: IGF-1 levels every 3-6 months (target age/sex-adjusted normal range; do not exceed +2 SD)
183- Growth response: height velocity should increase in first year of treatment (first-year catch-up is the best predictor of long-term response)
184- Side effects: injection site reactions, headache (pseudotumor cerebri — rare but check for papilledema), slipped capital femoral epiphysis, scoliosis progression, glucose intolerance
185
186### When to Stop GH Therapy
187- Growth velocity < 2 cm/year
188- Bone age closure (near adult height)
189- Patient/family desire to discontinue
190- Unacceptable side effects
191
192---
193
194## Checkpoint B — Growth Disorder Management Review
195
196- [ ] Serial height measurements plotted on appropriate growth chart (WHO or CDC)
197- [ ] Height velocity calculated and compared to age norms
198- [ ] Mid-parental height calculated and target range plotted
199- [ ] Bone age obtained and interpreted
200- [ ] Normal variants (FSS, CDGP) differentiated from pathologic growth failure
201- [ ] Tier 1 labs obtained (CBC, CMP, TSH, celiac, IGF-1, IGFBP-3)
202- [ ] Karyotype obtained for unexplained short stature in females
203- [ ] Tier 2/3 workup directed by clinical findings
204- [ ] Subspecialty referral placed if indicated (endocrine, genetics, GI)
205- [ ] GH therapy criteria evaluated if GHD confirmed
206- [ ] Pubertal staging documented at every growth visit
207- [ ] All [VERIFY] flags resolved or escalated
208
209---
210
211## Quality Audit
212
213| Item | Requirement | Pass? |
214|------|-------------|-------|
215| Serial measurements | ≥ 3 height data points plotted with velocity calculated | |
216| Growth chart selection | WHO < 2 years; CDC 2-20 years | |
217| MPH calculation | Both parents' heights used; target range plotted | |
218| Bone age | Obtained and interpreted with comparison to chronological age | |
219| Velocity assessment | cm/year calculated and compared to age norms | |
220| Tier 1 labs | CBC, CMP, TSH, celiac, IGF-1 all addressed | |
221| Turner screening | Karyotype considered for short females | |
222| Proportionality | Upper-to-lower segment ratio assessed (disproportionate = skeletal dysplasia) | |
223| Pubertal staging | Tanner stage documented | |
224| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |
225
226---
227
228## Guidelines
229
230- Use WHO growth standards (birth to 2 years) and CDC growth reference charts (2-20 years) per AAP
231- Follow Pediatric Endocrine Society guidelines for evaluation of short stature
232- Bone age assessment: Greulich-Pyle atlas is the most widely used method; Tanner-Whitehouse for research precision
233- GH stimulation testing: two failed stimulation tests required for GHD diagnosis (peak GH < 10 ng/mL on two separate tests)
234- FDA-approved GH indications: GHD, Turner, CRI, PWS, SGA, SHOX deficiency, ISS, Noonan
235- Turner syndrome: obtain karyotype in ALL girls with unexplained short stature (even without classic phenotypic features)
236- Celiac disease: may present with isolated short stature and no GI symptoms — always screen
237- Constitutional delay: bone age delay + family history of late puberty + normal growth velocity for bone age = reassurance; intervention only for significant psychosocial distress
238- IGF-1 reference ranges are age- and Tanner-stage-specific; do not use adult ranges for children
239- This skill produces clinical documentation; it does not replace clinical judgment